07:23 EDT Biogen (BIIB) up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: FDA Delay on Subcutaneous Lecanemab Seen as Timing Issue; Hold Rating Reiterated with Unchanged $203 Price Target
- Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA
- Remitly Global to replace Apellis in S&P 600 at open on 5/14
- Biogen upgraded to Buy from Hold at Freedom Broker
- Biogen price target raised to $190 from $189 at Truist